by Raynovich Rod | Apr 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in...
by Raynovich Rod | Apr 8, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To...
by Raynovich Rod | Apr 3, 2014 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update 4/4/14 Breach of Technicals-A Tad Below Early February Support Glut of Biotech IPOs Causing Indigestion? Momentum Days Are So Over NASDAQ Down 1.34% The volatile and speculative SPDR S&P Biotech XBI hit $136 in early trading down 2.28%.After a brief rally...
by Raynovich Rod | Apr 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the...
by Raynovich Rod | Mar 31, 2014 | Biopharmaceuticals
Large Cap Biopharmaceutical Growth Stocks With the MoMo days over the next earnings cycle (Q1,Q2 2014) should give us better clarity on winners for 2014.On the last day of March all of these large caps rallied after a severe one week correction from 3/21-28. Watch...
by Raynovich Rod | Mar 26, 2014 | Biopharmaceuticals
(See Full Article in Seeking Alpha 3/26) Biopharmaceutical Downdraft 15% From February Highs (IBB$239) Large Cap Biopharmaceutical Stocks Are Core Holdings: ABBV, AMGN, GILD The biotech frenzy of MoMo investing is over so it is time to invest longer term with quality...
by Raynovich Rod | Mar 18, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer...
by Raynovich Rod | Mar 17, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Life Science ETF's and Mutual Funds
XBI Outperforms FBIOX YTD Many biotech stocks sold off today despite a strong market on weak volume as industrials and tech were up about 1.4%. Watch the ETFs compared to Fidelity FBIOX because the sector is more volatile this month. Here is a chart comparing three...
by Raynovich Rod | Mar 13, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools, Life Science ETF's and Mutual Funds
March 17 Update -GREEN DAY with Geopolitical risk on back burner As of 11.38a EDT Industrials lead up 1%, healthcare up 0.8%, IBB up 1.33% Biopharmaceuticals stocks were strong with Rayno large cap picks: Alexion (ALXN $117) up 1.45%, Amgen (AMGN $125) up 1.9%,...
by Raynovich Rod | Mar 10, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Mini-Rally in Life Science Stocks— Update 10p PDT Biotech stocks recovered off their am lows today with major ETFs (FBT,IBB,XBI ($161.45) up about 0.3% and within 5% of highs. Over the past week or so biopharma stocks have been weak with a “topping”...
